TriangleAbemaciclib (NCT04469764)
Abemaciclib trial for Recurrent Endometrial Carcinoma (NCT04469764). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for female patients with recurrent epithelial ovarian, fallopian-tube, peritoneal, or endometrial cancer after chemotherapy for recurrence. Ovarian tumors require CDK4/6 activation; endometrial tumors must be endometrioid, hormone-receptor-positive, without CCNE amplification or RB loss.
The idea: abemaciclib blocks enzymes that drive cell growth. Patients take it orally twice daily in four-week cycles. Hormone-receptor-positive tumors receive anastrozole or letrozole to reduce estrogen production. Researchers measure disease control at sixteen weeks, response, and safety.
This phase 2 study plans 32 patients. Gottfried Konecny leads at UCLA, Los Angeles, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.